Meta-analysis on the diagnostic value of CYFRA21-1 in early non-small cell lung cancer

Objective: To evaluate the diagnostic value of CYFRA21-1 in early non-small cell lung cancer (NSCLC). Methods: All published clinical studies that evaluated the diagnostic value of CYFRA21-1 in non-small cell lung cancer were reviewed. The quality of the retrieved original studies was evaluated according to the requirements of meta-analysis. Meta-analysis was used in all eligible studies. Results: Nine studies including six in Chinese and three in English were collected. The sample size was 670 cases, of which 276 cases confirmed pathologically were in stage I - II and resectable. Heterogeneity test showed that the homogeneity of the studies was good. Deterministic model was used to analyze the data. The value of the weighted sensitivity was 41% (35%-46%), the specificity was 94% (91%-96%), the positive likelihood ratio was 5.65 (3.45-9.27), the negative likelihood ratio was 0.64 (0.54-0.76), and the SROC area under the curve (AUC) was 0.85. Conclusion: CYFRA21-1 can be regarded as a valuable marker in early NSCLC diagnosis; however, but more high-quality, large-sized and multi-center studies are still required to evaluate its clinical value.